CB2 receptors as new therapeutic targets for liver diseases

被引：85

作者：

Lotersztajn, S. ^{[1
,2
,3
]}

Teixeira-Clerc, F. ^{[1
,2
]}

Julien, B. ^{[1
,2
]}

Deveaux, V. ^{[1
,2
]}

Ichigotani, Y. ^{[1
,2
]}

Manin, S. ^{[1
,2
]}

Tran-Van-Nhieu, J. ^{[1
,2
,4
]}

Karsak, M. ^{[5
]}

Zimmer, A. ^{[5
]}

Mallat, A. ^{[1
,2
,3
]}

机构：

[1] Hop Henri Mondor, INSERM, U 841, Inst Mondor Rech Biomed, F-94010 Creteil, France

[2] Univ Paris 12, Creteil, France

[3] Grp Hosp Henri Mondor Albert Chenevier, AP HP, Serv Hepatol & Gastroenterol, Creteil, France

[4] Grp Hosp Henri Mondor Albert Chenevier, AP HP, Dept Pathol, Creteil, France

[5] Univ Bonn, Inst Mol Psychiat, D-5300 Bonn, Germany

来源：

BRITISH JOURNAL OF PHARMACOLOGY | 2008年 / 153卷 / 02期

关键词：

cannabinoid receptors; liver fibrosis; cirrhosis; ischaemia/reperfusion injury; liver diseases;

D O I：

10.1038/sj.bjp.0707511

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cannabinoid type-1 (CB1) and type-2 (CB2) receptors belong to the family of G protein-coupled receptors and mediate biological effects of phyto-derived and endogenous cannabinoids. Whereas functions of CB1 receptor have been extensively studied, the CB2 receptor has emerged over the last few years as a critical player in regulation of inflammation, pain, atherosclerosis and osteoporosis. Therefore, although still at a preclinical stage, the development of selective CB2 molecules has gained of interest as new targets in drug discovery. Recent data have unravelled a key role of CB2 receptors during chronic and acute liver injury, including fibrogenesis associated to chronic liver diseases, ischaemia-reperfusion-induced liver injury, and hepatic encephalopathy associated to acute liver failure. This review summarizes the latest advances on the recently identified role of CB2 receptors in the pathophysiology of liver diseases.

引用

页码：286 / 289

页数：4

共 26 条

[1]

Avraham Y, 2005, NEUROBIOL DIS, V12, P12

[2] Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury [J].